Review
Version 1
Preserved in Portico This version is not peer-reviewed
Role of LFA-1 and ICAM-1 in Cancer
Version 1
: Received: 28 September 2017 / Approved: 28 September 2017 / Online: 28 September 2017 (15:12:52 CEST)
Version 2 : Received: 28 September 2017 / Approved: 29 September 2017 / Online: 29 September 2017 (03:17:31 CEST)
Version 2 : Received: 28 September 2017 / Approved: 29 September 2017 / Online: 29 September 2017 (03:17:31 CEST)
A peer-reviewed article of this Preprint also exists.
Reina, M.; Espel, E. Role of LFA-1 and ICAM-1 in Cancer. Cancers 2017, 9, 153. Reina, M.; Espel, E. Role of LFA-1 and ICAM-1 in Cancer. Cancers 2017, 9, 153.
Abstract
The lymphocyte function–associated antigen-1 (LFA-1) (also CD11a/CD18 and alphaLbeta2), is just one of many integrins in the human body, but its significance derives from its exclusive presence in leukocytes. In this review, we summarize the studies relating LFA-1 and its major ligand ICAM-1 (CD54) with cancer, through the function of lymphocytes and myeloid cells on tumor cells. We consider how LFA-1 mediates the interaction of leukocytes with tumors and the role of ICAM-1 in tumor dynamics, which can be independent of its interaction with LFA-1. A more detailed examination of LFA’s role within B-cell chronic lymphocytic leukemia is made. Finally, we discuss the role of LFA-1-harboring exosomes in tumor growth and metastasis.
Keywords
cancer metastasis, chronic lymphocytic leukemia, exosomes, tumor microenvironment
Subject
Biology and Life Sciences, Cell and Developmental Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment